OSE Immunotherapeutics SA (EPA:OSE)

France flag France · Delayed Price · Currency is EUR
5.90
-0.25 (-4.07%)
Mar 28, 2025, 5:35 PM CET
Market Cap 129.05M
Revenue (ttm) 83.44M
Net Income (ttm) 37.45M
Shares Out 21.87M
EPS (ttm) 1.48
PE Ratio 3.99
Forward PE 7.56
Dividend n/a
Ex-Dividend Date n/a
Volume 167,511
Average Volume 132,792
Open 6.15
Previous Close 6.15
Day's Range 5.90 - 6.15
52-Week Range 4.51 - 11.58
Beta 0.82
RSI 38.14
Earnings Date Mar 28, 2025

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 55
Stock Exchange Euronext Paris
Ticker Symbol OSE
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.